애플, 사상 최고가...시총 3조7000억 달러 돌파 Ivar AI

Ambcrypto.com

Crypto market cap surpasses France, UK GDPs – India, Japan next

Financial Post

Hong Kong Stocks to Soar on China Stimulus Signals: Markets Wrap

InfoMoney

Alckmin: “É o maior acordo entre blocos do mundo. Um dia histórico”

Biztoc.com

Palantir's Stock Quadrupled in 2024. Can It Repeat in 2025?

Ubergizmo

Google Unveils Breakthrough Quantum Chip ‘Willow’

Raw Story

Google announces quantum computing chip breakthrough

GlobeNewswire

Gold Bullion Market Trends, Business Opportunities and Competitive Strategies, 2024-2028 & 2033 - Zijin Mining Group Co, Perth Mint, Johnson Matthey, Mitsubishi Materials, and Newmont Corp Dominate the Industry

Jornada.com.mx

Pactan el Mercosur y la UE acuerdo comercial histórico

The Daily Hodl

Crypto Investment Products Break Previous Record With $3,850,000,000 in Weekly Inflows: CoinShares

Biztoc.com

Mark Zuckerberg's Soaring Wealth: Billionaire Now Richer Than Warren Buffett, Mark Cuban, Peter Thiel And Ken Griffin Combined

Fark.com

China is surrounding Taiwan for some unknown reason which they aren't at liberty to discuss [Scary]

The Punch

Altseason Coming: Cardano, Solana, and New Altcoin Posed for Mind-blowing Gains

GlobeNewswire

The Rise of Social Media Management Market: A $ 51.8 billion Industry Dominated by IBM (US) and Cisco (US) | MarketsandMarkets™

Xataka.com

Uruguay ha conseguido que las guerras y la crisis del petróleo no les afecte. La transición a las renovables ha sido su escudo

BeInCrypto

La capitalización realizada de Ethereum registra máximo histórico y sugiere problemas para los bajistas de ETH

Meneame.net

EE.UU. anuncia nuevas restricciones tecnológicas a China para frenar su avance en microchips avanzados

newsBTC

Ethereum Price Breakout: Charting The Uncertain Part Of ETH To $18,000

$Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma$

GlobeNewswire

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma